Paradox Immunotherapeutics

Paradox Immunotherapeutics is a preclinical-stage biotechnology company founded in 2019, operating from Toronto, Canada. The firm is focused on creating monoclonal antibody (mAb) treatments for protein misfolding diseases, such as various forms of amyloidosis. These conditions occur when proteins fail to form their correct shape, leading to the creation of toxic deposits that disrupt tissue and organ function. The company's business model centers on the discovery and development of these specialized antibody therapies, which are designed to selectively target and clear only the harmful misfolded proteins, leaving healthy proteins unharmed.

The company was co-founded by Dr. Natalie Galant, who serves as CEO, and Dr. Yulong Sun, the Chief Scientific Officer. Both founders earned their PhDs in medical biophysics from the University of Toronto. Dr. Galant's doctoral research contributed to the development of a monoclonal antibody for cardiac amyloidosis, which is now in FDA clinical trials after being part of a $1.2 billion acquisition deal in 2021. This background provides the foundational science for Paradox's proprietary drug discovery platform. The platform utilizes a structural-based algorithm to predict specific regions on a protein that emerge during misfolding, enabling the creation of antibodies that precisely target these deviant forms.

Paradox Immunotherapeutics serves patients with rare and life-threatening diseases that currently have ineffective treatment options. The company's pipeline includes candidates like LX-96 for immunoglobulin light chain (AL) amyloidosis, KX-99 for leukocyte chemotactic factor 2 (LECT2) amyloidosis which affects the kidneys, and NX-86 for neurodegenerative diseases. In February 2025, the company secured $10 million in financing led by SymBiosis Capital Management to advance its therapeutic pipeline toward clinical milestones. This funding followed numerous recognitions, including being a finalist at J.P. Morgan's Life Sciences Innovation Summit and a winner at the BIO Emerging Company Start-Up Stadium.

Keywords: protein misfolding diseases, antibody therapies, monoclonal antibodies, amyloidosis, drug discovery platform, preclinical biotech, immunotherapy, AL amyloidosis, LECT2 amyloidosis, neurodegenerative diseases, biotherapeutics, rare diseases, structural-based drug design, targeted therapy, immunoglobulin light chain amyloidosis, chronic kidney disease, Yulong Sun, Natalie Galant, SymBiosis Capital Management